Visceral leishmaniasis in a patient with ulcerative colitis: A case report

Introduction. There is a rise of visceral leishmaniasis in immunocompromised patients due to increased availability of immunomodulatory drugs. In order to point at the occurrence of visceral leishmaniasis in patients with inflammatory bowel disease (IBD), we reported a case of female patient with a...

Full description

Bibliographic Details
Main Authors: Janković Goran, Martinović Lena, Dakić Zorica, Mijač Dragana, Štulić Miloš, Krstić Miodrag
Format: Article
Language:English
Published: Military Health Department, Ministry of Defance, Serbia 2020-01-01
Series:Vojnosanitetski Pregled
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800076J.pdf
id doaj-312c9e45c7f44945a829953857cbb440
record_format Article
spelling doaj-312c9e45c7f44945a829953857cbb4402020-11-25T03:10:02ZengMilitary Health Department, Ministry of Defance, SerbiaVojnosanitetski Pregled0042-84502406-07202020-01-0177443543910.2298/VSP180302076J0042-84501800076JVisceral leishmaniasis in a patient with ulcerative colitis: A case reportJanković Goran0Martinović Lena1Dakić Zorica2Mijač Dragana3Štulić Miloš4Krstić Miodrag5Clinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaClinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaUniversity of Belgrade, Faculty of Medicine, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Department of Microbiology, Belgrade, SerbiaClinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaClinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaClinical Center of Serbia, Clinic for Gastroenterology and Hepatology, Belgrade, Serbia + University of Belgrade, Faculty of Medicine, Belgrade, SerbiaIntroduction. There is a rise of visceral leishmaniasis in immunocompromised patients due to increased availability of immunomodulatory drugs. In order to point at the occurrence of visceral leishmaniasis in patients with inflammatory bowel disease (IBD), we reported a case of female patient with a travel history to European Mediterranean countries, who was on immunosuppressive treatment due to ulcerative colitis. Case report. A 29-year-old female patient was admitted to hospital due to severe relapse of ulcerative colitis. Corticosteroid therapy was administered in addition to previous longterm azathioprine, with clinical response to the treatment. During the course of the disease she had recurrent high-grade fever with marked hepatosplenomegaly and pancytopenia. The diagnosis of leishmaniasis was established by positive serology tests and microscopic finding of amastigotes in bone marrow smears. The disseminated infection was responsive to treatment with liposomal amphotericin B, but therapy had to be discontinued due to urticarial rush. Subsequent therapy with antimony was administered, but it had to be stopped too due to liver toxicity. No further treatment for leishmaniasis was initiated as the clinical and laboratory data suggested that the patient had responded to the treatment. She was discharged from hospital in IBD remission and without signs of the infection. Conclusion. Visceral leishmaniasis should be considered in IBD patients with fever of unknown origin and relevant travel history in order to achieve favorable disease outcome.http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800076J.pdfcolitis, ulcerativediagnosisimmunosuppressive agentsleishmaniasisrisk assessmentserology
collection DOAJ
language English
format Article
sources DOAJ
author Janković Goran
Martinović Lena
Dakić Zorica
Mijač Dragana
Štulić Miloš
Krstić Miodrag
spellingShingle Janković Goran
Martinović Lena
Dakić Zorica
Mijač Dragana
Štulić Miloš
Krstić Miodrag
Visceral leishmaniasis in a patient with ulcerative colitis: A case report
Vojnosanitetski Pregled
colitis, ulcerative
diagnosis
immunosuppressive agents
leishmaniasis
risk assessment
serology
author_facet Janković Goran
Martinović Lena
Dakić Zorica
Mijač Dragana
Štulić Miloš
Krstić Miodrag
author_sort Janković Goran
title Visceral leishmaniasis in a patient with ulcerative colitis: A case report
title_short Visceral leishmaniasis in a patient with ulcerative colitis: A case report
title_full Visceral leishmaniasis in a patient with ulcerative colitis: A case report
title_fullStr Visceral leishmaniasis in a patient with ulcerative colitis: A case report
title_full_unstemmed Visceral leishmaniasis in a patient with ulcerative colitis: A case report
title_sort visceral leishmaniasis in a patient with ulcerative colitis: a case report
publisher Military Health Department, Ministry of Defance, Serbia
series Vojnosanitetski Pregled
issn 0042-8450
2406-0720
publishDate 2020-01-01
description Introduction. There is a rise of visceral leishmaniasis in immunocompromised patients due to increased availability of immunomodulatory drugs. In order to point at the occurrence of visceral leishmaniasis in patients with inflammatory bowel disease (IBD), we reported a case of female patient with a travel history to European Mediterranean countries, who was on immunosuppressive treatment due to ulcerative colitis. Case report. A 29-year-old female patient was admitted to hospital due to severe relapse of ulcerative colitis. Corticosteroid therapy was administered in addition to previous longterm azathioprine, with clinical response to the treatment. During the course of the disease she had recurrent high-grade fever with marked hepatosplenomegaly and pancytopenia. The diagnosis of leishmaniasis was established by positive serology tests and microscopic finding of amastigotes in bone marrow smears. The disseminated infection was responsive to treatment with liposomal amphotericin B, but therapy had to be discontinued due to urticarial rush. Subsequent therapy with antimony was administered, but it had to be stopped too due to liver toxicity. No further treatment for leishmaniasis was initiated as the clinical and laboratory data suggested that the patient had responded to the treatment. She was discharged from hospital in IBD remission and without signs of the infection. Conclusion. Visceral leishmaniasis should be considered in IBD patients with fever of unknown origin and relevant travel history in order to achieve favorable disease outcome.
topic colitis, ulcerative
diagnosis
immunosuppressive agents
leishmaniasis
risk assessment
serology
url http://www.doiserbia.nb.rs/img/doi/0042-8450/2020/0042-84501800076J.pdf
work_keys_str_mv AT jankovicgoran visceralleishmaniasisinapatientwithulcerativecolitisacasereport
AT martinoviclena visceralleishmaniasisinapatientwithulcerativecolitisacasereport
AT dakiczorica visceralleishmaniasisinapatientwithulcerativecolitisacasereport
AT mijacdragana visceralleishmaniasisinapatientwithulcerativecolitisacasereport
AT stulicmilos visceralleishmaniasisinapatientwithulcerativecolitisacasereport
AT krsticmiodrag visceralleishmaniasisinapatientwithulcerativecolitisacasereport
_version_ 1724661031631847424